Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nicotinamide Phosphoribosyl Transferase (Nampt) Is a Target of MicroRNA-26b in Colorectal Cancer Cells

29 Jul 2013

Abstract excerpt

A number of cancers show increased expression of Nicotinamide phosphoribosyl transferase (Nampt). However, the mechanism through which Nampt is upregulated is unclear. In our study, we found that the Nampt-specific chemical inhibitor FK866 significantly inhibited cell survival and reduced nicotinamide adenine dinucleotide (NAD) levels in LoVo and SW480 cell lines. Bioinformatics analyses suggested that miR-26b...

Topics

Join the communities discussing this publication.

Autophagy in Disease and Therapy
Biochemical and Molecular Research
RNA modifications and cancer

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 23922874
DOI: 10.1371/journal.pone.0069963

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nicotinamide Phosphoribosyl Transferase (Nampt) Is a Target of MicroRNA-26b in Colorectal Cancer CellsPMID 23922874Read ↗

Downregulation of miR-182-5p by NFIB promotes NAD+ salvage synthesis in colorectal cancer by targeting NAMPTSemantic proximity Read ↗

Targeting the NAD+ salvage pathway suppresses APC mutation-driven colorectal cancer growth and Wnt/β-catenin signaling via increasing Axin level.Semantic proximity Read ↗

Updated Functional Roles of NAMPT in Carcinogenesis and Therapeutic NichesSemantic proximity Read ↗

Advances in NAD-Lowering Agents for Cancer TreatmentSemantic proximity Read ↗

Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD+ biosynthesis pathway and NAMPT mutation.Semantic proximity Read ↗

NAMPT Is a Potent Oncogene in Colon Cancer Progression that Modulates Cancer Stem Cell Properties and Resistance to Therapy through Sirt1 and PARPSemantic proximity Read ↗

Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracilSemantic proximity Read ↗

Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug DiscoverySemantic proximity Read ↗

Downregulated SIRT6 and upregulated NMNAT2 are associated with the presence, depth and stage of colorectal cancerSemantic proximity Read ↗

Discovery and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferaseSemantic proximity Read ↗

The NAMPT Inhibitor FK866 in Combination with Cisplatin Reduces Cholangiocarcinoma Cells GrowthSemantic proximity Read ↗

NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic TargetsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.